Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluorescence-guided oral cancer surgery with cRGD-ZW800-1
NL-OMON60719Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Dec 2024
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cRGD-ZW800-1 in Oral Mucosal Carcinoma and mouth cancer, sponsored by Erasmus MC. Primary endpoints: Rate of adequate tumor resection margins and Recommended dose for tumor-to-background ratio. Started Dec 2024; status: completed.
02
Drugs
cRGD-ZW800-1
03
Conditions
Oral Mucosal Carcinomamouth cancer
Beyond the preview
Go deeper on NL-OMON60719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60719.